Skip to main content
. 2020 Apr 3;10:5843. doi: 10.1038/s41598-020-62665-w

Figure 10.

Figure 10

Effects of p38 MAPK inhibitor (SB239063) on levels of p-ezrin, intracellular ATP and ROS. (A) Immunoreactive bands of p-ezrin and total ezrin in high glucose-treated cells without or with SB239063 cotreatment. (B) Band intensity of p-ezrin normalized with total ezrin in high glucose-treated cells without or with SB239063 cotreatment. (C) Intracellular ATP level detected by luciferin-luciferase ATP assay. (D) Intracellular ROS level measured by DCFH-DA assay and flow cytometry. Each bar represents mean ± SEM of the data obtained from three independent samples. *p < 0.05 vs. high glucose.